Comparative Pharmacology
Head-to-head clinical analysis: AMINESS 5 2 ESSENTIAL AMINO ACIDS W HISTADINE versus AMINOSYN HBC 7 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINESS 5 2 ESSENTIAL AMINO ACIDS W HISTADINE versus AMINOSYN HBC 7 IN PLASTIC CONTAINER.
AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE vs AMINOSYN-HBC 7% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Provides essential amino acids and histidine for protein synthesis in patients unable to tolerate oral or enteral nutrition, supporting nitrogen balance and tissue repair. The amino acids are utilized for anabolic processes and metabolic pathways.
Provides essential and nonessential amino acids to support protein synthesis and nitrogen balance in patients with metabolic stress or hepatic encephalopathy.
Intravenous infusion: 500 mL of 5.2% solution (26 g amino acids) over 8-12 hours daily, providing 0.8-1.2 g/kg/day of amino acids depending on metabolic needs.
1-2 L/day intravenously (equivalent to 70-140 g amino acids/day) for adults; infuse at no more than 0.1 g/kg/h.
None Documented
None Documented
Approximately 2-4 hours for most essential amino acids; clinical context: rapid clearance necessitates continuous infusion for stable plasma levels.
Terminal elimination half-life of infused amino acids is approximately 0.5-1 hour for free amino acids, but varies by individual amino acid. Clinical context: rapid clearance in critically ill patients due to increased metabolic demand.
Renal: >95% as amino acids and metabolites; negligible biliary/fecal.
Renal: 100% of infused amino acids are metabolized or excreted renally as urea and other nitrogenous waste products. No biliary or fecal elimination.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution